Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Pharmaceuticals. Mr Doyle brings extensive knowledge in leading negotiations for pharmaceutical assets across a range of deal types, licensing deals across multiple geographies and commercialisation strategies.
BRISBANE, Australia , Aug. 5, 2024 /PRNewswire/ -- QBiotics Group Limited ( QBiotics ) is pleased to announce the appointment of Stephen Doyle , as Chief Executive Officer effective 2 September 2024 . Mr Doyle is a global pharmaceutical executive with more than 24 years' experience gained across a range of specialties within the medical and pharmaceutical sectors in both developed and emerging markets.
A pharmacist by training, Stephen has held a number of senior leadership roles at top pharmaceutical companies globally during the past two decades. Starting his career at Janssen Cilag and Novartis in Sydney , he was appointed to lead medical affairs of the Oncology Business Unit at Sanofi Aventis (later Sanofi). Over the next ten years, the expansion of Stephen's remit within Sanofi saw him relocating to Europe and Asia to oversee scientific communications, then commercial operations of the oncology arm in each market.
As Vice President of Oncology, Haematology and Transplantation Business Unit in Shanghai , Stephen launched new indica.